loader2
Partner With Us NRI

Glaxosmithkline Pharmaceuticals Ltd share Price Today

Company details

2,829.05
2,966.95
1,385.05
2,966.95
6M Return 34.94%
1Y Return 105.35%
Mkt Cap.(Cr) 49,226.84
Volume 139,605
Div Yield 1.13%
OI
-
OI Chg %
-
Volume 139,605
NSE

Open Free Trading Account Online with ICICIDIRECT

Incur '0' Brokerage upto ₹500

Pharmaceuticals company GlaxoSmithKline Pharmaceuticals announced Q1FY25 results:

Financial Highlights: 

  • GlaxoSmithKline Pharmaceuticals Limited (GSK) today announced its financial results for quarter ended June 30, 2024. Revenue from operations for the quarter grew by 10% at Rs 811 crore. Profit After Tax (PAT) for the quarter at Rs 182 crore.
  • The company continued to deliver a strong growth of 10% with key brands such as Calpol, Augmentin, T-Bact and gaining market share. In addition, the Respiratory portfolio comprising Nucala and Trelegy delivered a growth of 57% by further improving access to more patients.

Commenting on the results, Bhushan Akshikar, Managing Director, GlaxoSmithKline Pharmaceuticals, said “We continue our growth momentum across General Medicines and Vaccines portfolios while maintaining profitability. As we celebrate hundred years of our operations in India, we remain committed to pursuing new growth opportunities, enhancing our leadership in key therapeutic areas and advancing our innovative omnichannel strategies to further enhance customer experience.”

Result PDF

View Other Company Results

Glaxosmithkline Pharmaceuticals Ltd shares SWOT Analysis

Strengths (6)

  • Strong Momentum: Price above short, medium and long term moving averages
  • New 52 week high today
  • Effectively using its capital to generate profit - RoCE improving in last 2 years

Weakness (4)

  • Inefficient use of shareholder funds - ROE declining in the last 2 years
  • Inefficient use of assets to generate profits - ROA declining in the last 2 years
  • Decline in Net Profit (QoQ)

Opportunity (2)

  • Highest Recovery from 52 Week Low
  • RSI indicating price strength

Threats (2)

  • High PE (PE > 40)
  • Increasing Trend in Non-Core Income
Discover More

Resistance and support

R1 2,972.2
R2 3,038.5
R3 3,110.1
Pivot

2,900.62

S1 2,834.3
S2 2,762.7
S3 2,696.4
EMA SMA
2,774.7
2,640.1
2,463.5
2,215.0
2,763.7
2,657.0
2,378.8
2,157.1
Delivery and volume
Discover More
CLIENT NAME DEAL TYPE ACTION DATE AVG. PRICE QUANTITY EXCHANGE
ISHARES CORE MSCI EMERGING MARKETS ETF Block Purchase 2022-10-17 1378.65 80615 BSE
ISHARES MSCI INDIA SMALL-CAP ETF Block Purchase 2022-10-17 1378.65 11841 BSE
ISHARES CORE EMERGING MARKETS MAURITIUS CO Block Sell 2022-10-17 1378.65 80615 BSE
Discover More
Name Category Shares
GLAXO GROUP LIMITED PROMOTER 35.99%
GLAXOSMITHKLINE PTE LIMITED PROMOTER 28.1%
ESKAYLAB LIMITED PROMOTER 6.94%
BURROUGHS WELLCOME INTERNATIONAL LIMITED PROMOTER 3.97%

FINANCIALS

Sales
Operating Profit
Profit after Tax
DISCOVER MORE
Equity
Reserves and Surplus
Debt
DISCOVER MORE
Sales
Operating Profit
Profit after Tax
DISCOVER MORE
PE
Debt/Equity
P BV
DISCOVER MORE

Glaxosmithkline Pharmaceuticals Ltd Stocks COMPARISON

Financials( ₹ in Cr) Glaxosmithkline Pharmaceuticals Ltd Sun Pharmaceuticals Industries Ltd Cipla Ltd Divis Laboratories Ltd Zydus Lifesciences Ltd
Price 2,905.85 1,742.75 1,576.10 4,633.90 1,187.55
% Change 2.97 0.06 0.79 -0.60 1.46
Mcap ₹ Cr 49,226.84 418,144.11 127,272.91 123,015.68 119,495.32
Revenue TTM ₹ Cr 3,453.71 48,496.85 25,774.09 7,845.00 19,547.40
Net Profit TTM ₹ Cr 589.96 9,648.44 4,155.31 1,600.00 3,854.40
PE TTM 62.03 39.62 28.43 73.92 28.26
1 Year Return 105.35 53.65 27.56 24.21 85.08
ROCE 44.97 17.20 22.27 16.41 23.94
ROE 37.32 16.13 16.58 12.15 20.64
DISCOVER MORE
INSIDER & INSTITUTIONAL ACTIVITY

Equity Capital: 1,777.64 Cr FV: 10.00

Period MF Net Purchase / (sold) FII Net
LAST 1M 37,516.17 -14,555.25
LAST 3M 90,902.40 37,557.41
LAST 6M 198,345.87 43,710.77
LAST 12M 329,168.77 54,053.10
GlaxoSmithKline Pharmaceuticals Limited - Loss of Share Certificates

Aug 14, 2024 l NSE Announcement

GlaxoSmithKline Pharmaceuticals Limited - Other General Purpose

Aug 13, 2024 l NSE Announcement

DISCOVER MORE
Date Action Type Ratio
May 31, 2024 Dividend 320
Jun 30, 2023 Dividend 320
Jul 07, 2022 Dividend 300
DISCOVER MORE

Glaxosmithkline Pharmaceuticals Ltd Information

Stock PE (TTM)
62.03
Promoter Holding
75%
Book Value
104.9337
ROCE
44.97%
ROE
37.32%
Description

  • GlaxoSmithKline Pharmaceuticals Ltd is in the Pharmaceuticals sector is having a market capitalization worth Rs. 25,676.02 crores, it is incorporated in the year 1924. It has reported consolidated sales of Rs. 789.99 crores in June 2021. The company is listed on the Bombay Stock Exchange (BSE) with the code 500660, and also listed on the National Stock Exchange (NSE) with the code GLAXO.

    GlaxoSmithKline Pharmaceuticals is one of the leading manufacturers of pharmaceuticals and vaccines in India. GSK entered the Indian market under the name of H J Foster & Co Ltd. The company generated 76% of its revenue from the selling and distribution of pharmaceuticals while the vaccine segment generated 24% of its revenue. 5 of the brands marketed by GSK feature in the India Pharmaceutical Market. These brands are (i) Augmentin, (ii) Betnovate, (iii) Calpol, (iv) Ceftum, and (v) Synflorix. GSK has a developed a team of over 5,000 employees spread across the country. GSK has also established two global Research & Development centers in the country. The promoters of the company own 75.0% of the stake in the company, Foreign Institutional Investors (FII) own 1.61% of the stake, Domestic Institutional Investors (DII) own 10.92%, and others (such as public & retail investors) hold the balance of 12.47%.

    In June 2021, quarterly net revenue was Rs. 773.46 crores, which has increased by approximately 19.24 % from Rs. 648.65 crores for the April-June 2020 quarter. The quarterly net profit in June 2021 was Rs. 120.4 crores, which has improved sharply and increased by nearly 8.51% from a net profit of Rs. 110.96 crores in June 2020. In June 2021, the reported operating profit was at Rs. 645.05 crores, which is increased by 10.95% as compared to an operating profit of Rs. 581.39 crores for the quarter ending in June 2020. From an EPS of Rs. 6.55 in June 2020, the EPS of Glaxosmithkline Pharmaceuticals Ltd has improved and reached an EPS of Rs. 7.11 per share in June 2021. GLAXO's stock closed at Rs. 1,515.65 on 27th August’2021 (NSE). GlaxoSmithKline Pharmaceuticals Ltd has returned 3.77% in the last six months and returned 5.18% negatively in the previous year.

Read More
Registered Address

GSK House, Dr Annie Besant Road Worli, Mumbai, Maharashtra, 400030

Tel : 91-022-24959595
Email : askus:gsk.com; ajay.a.nadkarni:gsk.com
Website : http://www.gsk-india.com
Registrar

Karvy Computershare Pvt Ltd

AGM Date (Month) : Jul
Face Value Equity Shares : 10
Market Lot Equity Shares : 1
BSE Code : 500660
NSE Code : GLAXO
Book Closure Date (Month) :
BSE Group : A
ISIN : INE159A01016

FAQ’s on Glaxosmithkline Pharmaceuticals Ltd Shares

You can buy Glaxosmithkline Pharmaceuticals Ltd shares through a brokerage firm. ICICIdirect is a registered broker through which you can place orders to buy Glaxosmithkline Pharmaceuticals Ltd Share.

Company share prices and volatile and keep changing according to the market conditions. As of Aug 16, 2024 04:00 PM the closing price of Glaxosmithkline Pharmaceuticals Ltd was Rs.2,905.85.

The latest PE ratio of Glaxosmithkline Pharmaceuticals Ltd as of Aug 16, 2024 04:00 PM is 62.03

The latest PB ratio of Glaxosmithkline Pharmaceuticals Ltd as of Aug 16, 2024 04:00 PM is 0.04

The 52-week high of Glaxosmithkline Pharmaceuticals Ltd share price is Rs. 2,966.95 while the 52-week low is Rs. 1,385.05

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of Aug 16, 2024 04:00 PM, the market cap of Glaxosmithkline Pharmaceuticals Ltd stood at Rs. 49,226.84 Cr.

Download App

Download Our App

Play Store App Store
market app